SRC and prostate cancer: The CC chemokine ligand (CCL2)-CCR2 axis is involved in multi-tyrosine kinase inhibition and microtubule inhibition resistance in the colon and prostate cancer cells [33,34], and CCR2 promotes cell growth and cell cycle progression via Src and Akt activation in breast cancer cells [35].